The cellular biology of the Reed-Sternberg cell [see comments]

Autor: FG Haluska, AM Brufsky, GP Canellos

Publikováno v: Blood. 84:1005-1019

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c353558defd764c75cd912f35e07423
https://doi.org/10.1182/blood.v84.4.1005.1005

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.

Autor: Freedman RA; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston. Electronic address: Rachel_freedman@dfci.harvard.edu., Heiling HM; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Li T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Trapani D; Division of New Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; Department of Oncology and Hematology, University of Milan, Milan, Italy., Tayob N; Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA., Smith KL; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Davis R; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Pereslete AM; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Cotter C; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Chen WY; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Parsons HA; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Santa-Maria CA; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Van Poznak C; Department of Internal Medicine, University of Michigan, Ann Arbor., Moy B; Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston., Brufsky AM; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh., Melisko ME; Division of Hematology and Oncology, University of California at San Francisco, San Francisco., O'Sullivan CC; Medical Oncology, Mayo Clinic, Rochester., Ashai N; Department of Medicine, Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington., Rauf Y; Department of Neurology, University of North Carolina, Chapel Hill., Nangia JR; Department of Medicine and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston., Burns RT; Department of Medicine, Yale Cancer Center, New Haven, USA., Savoie J; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston., Wolff AC; Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore., Winer EP; Department of Medicine, Yale Cancer Center, New Haven, USA., Rimawi MF; Department of Medicine and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston., Krop IE; Department of Medicine, Yale Cancer Center, New Haven, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Cancer Institute, Boston.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Nov; Vol. 35 (11), pp. 993-1002. Date of Electronic Publication: 2024 Jul 06.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Autor: Nader-Marta G; Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium. guilherme_nadermarta@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. guilherme_nadermarta@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. guilherme_nadermarta@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. guilherme_nadermarta@dfci.harvard.edu., Singer C; Department of Obstetrics and Gynaecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Hlauschek D; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., DeMichele A; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., de Azambuja E; Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium., Pfeiler G; Department of Obstetrics and Gynaecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Martin M; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Balko JM; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Nowecki Z; The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Balic M; Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.; University of Pittsburgh Hillman Cancer Center, Magee-Women's Hospital, Pittsburgh, PA, USA., Brufsky AM; University of Pittsburgh Hillman Cancer Center, Magee-Women's Hospital, Pittsburgh, PA, USA., Chan A; Breast Cancer Research Centre-WA & Curtin University, Perth, Australia., Morris PG; Cancer Trials Ireland, Dublin, Ireland.; Beaumont RCSI Cancer Centre, Dublin, Ireland., Haddad T; Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Loibl S; German Breast Group, Prof. (Apl), Goethe University Frankfurt, Frankfurt am Main, Germany.; Clinical Consultant Centre for Haematology and Oncology/Bethanien, Frankfurt, Germany., Liu Y; Translational Oncology Global Product Development Pfizer Inc, San Diego, CA, USA., Soelkner L; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., Fesl C; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., Mayer EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2024 Oct 07; Vol. 26 (1), pp. 140. Date of Electronic Publication: 2024 Oct 07.

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.

Autor: Mamounas EP; Orlando Health Cancer Institute, Orlando, Florida., Bandos H; NRG Oncology SDMC, and the University of Pittsburgh, Pittsburgh, Pennsylvania., Rastogi P; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Magee-Womens Hospital, Pittsburgh, Pennsylvania., Zhang Y; Biotheranostics, Inc., A Hologic Company, San Diego, California., Treuner K; Biotheranostics, Inc., A Hologic Company, San Diego, California., Lucas PC; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Geyer CE Jr; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Fehrenbacher L; Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, California., Chia SK; British Columbia Cancer Agency, and the University of British Columbia, Vancouver, British Columbia, Canada., Brufsky AM; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; Magee-Womens Hospital, Pittsburgh, Pennsylvania., Walshe JM; Cancer Trials Ireland (formerly known as Irish Clinical Oncology Research Group-ICORG), Dublin, Ireland., Soori GS; Florida Cancer Specialists, Ft. Myers, Florida., Dakhil S; CCOP Wichita/Cancer Center of Kansas, Wichita, Kansas., Paik S; Theragenbio, Inc., Pankyo, Republic of South Korea, and Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of South Korea., Swain SM; Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia., Sgroi DC; Massachusetts General Hospital, Boston, Massachusetts., Schnabel CA; Biotheranostics, Inc., A Hologic Company, San Diego, California., Wolmark N; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 01; Vol. 30 (9), pp. 1984-1991.

Omission of surgery, primary endocrine therapy adherence, and effect of comorbidity in older women with estrogen receptor positive breast cancer.

Autor: Carleton N; Women's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Abidi H; Division of Breast Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, PA, USA., Puthanmadhom-Narayanan S; Department of Medicine, University of Pittsburgh School of Medicine, PA, USA., Marroquin OC; UPMC Clinical Analytics, UPMC Health Services Division, USA., Oesterreich S; Women's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Diego EJ; Division of Breast Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, PA, USA., Brufsky AM; Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Lee AV; Women's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., McAuliffe PF; Women's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Division of Breast Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, PA, USA. Electronic address: mcauliffepf@upmc.edu.

Publikováno v: Journal of geriatric oncology [J Geriatr Oncol] 2024 Apr; Vol. 15 (3), pp. 101679. Date of Electronic Publication: 2023 Dec 21.